Frontiers in Oncology (Mar 2019)

Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature

  • Ibrahim Abu-Gheida,
  • Samuel Chao,
  • Erin Murphy,
  • John Suh,
  • Glen H. Stevens,
  • Alireza M. Mohammadi,
  • Michael McNamara,
  • Jennifer S. Yu,
  • Jennifer S. Yu

DOI
https://doi.org/10.3389/fonc.2019.00168
Journal volume & issue
Vol. 9

Abstract

Read online

Melanoma brain metastasis with ependymal spread/metastases is uncommon. These cases are frequently classified together with leptomeningeal disease. However, the commonalities and differences in the underlying pathophysiology and clinical outcomes between these two types of spread are not clear. Very few reports on long term outcome and durable central nervous system (CNS) disease control have been reported in the literature. Here, we report a case of a 45 year-old Caucasian lady with BRAF-V600E mutant metastatic melanoma to the brain who had whole brain radiotherapy followed by two Gamma knife radiosurgery treatments for localized disease progression. She then developed extensive ependymal disease progression with no evidence of leptomeningeal spread. She was treated with a repeat course of whole brain radiotherapy and maintained on BRAF and MEK inhibitors with durable CNS disease control for more than a year. This study reviews the management of BRAF-V600E mutant melanoma with ependymal involvement. Management using radiation therapy with maintenance targeted therapy seems to be a reasonable approach to this challenging disease.

Keywords